Medicamen Biotech Dividend FY26 – ₹1/Share | Yield 0.31% | Record Date 19 Sep 2026

Medicamen Biotech Limited (CIN: L74899DL1993PLC056594) is a Delhi-headquartered pharmaceutical company specializing in Generic Finished Dosage Forms, Oncology Formulations, and Contract Research & Development services. The company operates across global regulated and semi-regulated markets, serving the pharmaceutical supply chain with manufacturing capabilities in oral solids, injectables, and oncology products. Incorporated in 1993, Medicamen reported consolidated revenue of ₹197.77 Cr for FY2025-26 with a net profit of ₹9.64 Cr. The company's equity is held 40.46% by promoter entity Shivalik Rasayan Limited, with zero promoter pledging. At a current market price of approximately ₹319, the stock trades at a P/E of ~39x, classifying it as a small-cap pharma stock with a market capitalization of ₹432.65 Cr.

Medicamen Biotech has paid dividends 10 times since 2002, distributing a cumulative ₹9.25 per share over this period. The company maintained a flat ₹1 per share dividend for six consecutive years (FY21–FY26), except FY20 when it was halved to ₹0.50. The dividend has shown zero growth despite earnings fluctuating significantly. Classification: Consistent but Stagnant Payer — reliable at ₹1/share but no real growth in payout even when profits were higher. The rising yield trend (0.09% → 0.37%) reflects the falling share price, not a dividend increase. (Sources: Trendlyne, StockPriceArchive, Simply Wall St)

The Face-Value Illusion: Medicamen Biotech's "10% dividend" sounds attractive until you decode what it actually means. The 10% is calculated on the ₹10 face value, not the market price. In reality, shareholders receive just ₹1 per share — which at a CMP of ~₹319 translates to a yield of merely 0.31%. A fixed deposit yields 10–15x more. The company has maintained an identical ₹1/share payout for six straight years regardless of whether profits were ₹14.90 Cr (FY22) or ₹6.56 Cr (FY25). This mechanical constancy raises questions about whether the board views dividends as a genuine capital return tool or merely a formality. The total outflow of ₹1.36 Cr against FY26 PAT of ₹9.64 Cr (payout ratio: 14.07%) shows the company is barely sharing profits with shareholders.

Medicamen's revenue recovery in FY26 (+21.67% YoY) suggests some operational stabilization, but the structural margin compression from FY22 (20.9% OPM) to FY26 (~10% OPM) remains a concern. Employee costs rising to 19.14% of revenue reflect either business model dilution or capacity build-out for future growth. Q1 FY27 results (Apr–Jun 2026) showed revenue of ₹47.90 Cr (up 11.3% YoY) with PAT of ₹4.45 Cr (up 178% YoY from a low base of ₹1.60 Cr). The negative OCF of -₹33 Cr is the most pressing concern — the company is generating accounting profits but consuming cash operationally, possibly due to rising receivables or inventory build-up. Future dividend growth hinges entirely on whether management can convert profits into actual cash flows and arrest the multi-year margin compression trend.

On 14 August 2026, Medicamen Biotech Limited's Board of Directors recommended a Final Dividend of Re. 1 per equity share (10% on Face Value of ₹10) for FY2025-26 at its board meeting. The dividend was subject to approval by shareholders at the 33rd Annual General Meeting held on 26 September 2026 via video conferencing. The record date was fixed as 19 September 2026 (Saturday), making the ex-dividend date 18 September 2026 (Friday). Books were closed from 20–26 September 2026. Payment is expected by 26 October 2026. The CMP on the announcement date was approximately ₹240.75, giving an announcement-date yield of 0.42%. As of today, the record date has passed and only shareholders who held shares before the ex-date are eligible for this dividend. (Source: BSE Filing, Regulation 30 LODR)

Note: The record date (19 Sep 2026) and ex-date (18 Sep 2026) have already passed. This dividend is now in the payment phase.

Medicamen has paid dividends in 10 of the 24 years since its first payout in 2002, making it an irregular historical payer that turned consistent post-2017. The last six consecutive years (FY21–FY26) saw an identical ₹1/share payout — a mechanical repetition regardless of earnings. In FY22, when EPS was ₹12.19, the company paid just ₹1 (payout: 8.2%). In FY25, with EPS at ₹5.16, the payout ratio rose to 19.4% — not because the dividend grew, but because earnings shrank. The single exception was FY20 (₹0.50, a COVID-year cut). There have been no special dividends or bonus issues. Classification: Consistent but Stagnant Payer. Shareholders receiving the same nominal amount year after year are effectively losing purchasing power to inflation. (Sources: Trendlyne, Simply Wall St)

Operating Leverage Alert: Revenue grew 21.67% in FY26, but operating margins only marginally improved from 8.9% to ~10%. This means the company is growing topline but not converting it proportionally to bottom line — a sign of cost-side pressure. Employee costs, the largest non-material expense, rose from 12.17% (FY22) to 19.14% (FY25) of revenue. The 4-year PAT CAGR is -10.31%, meaning profits have shrunk at a double-digit rate despite revenue growing at a 14.4% CAGR. This divergence between topline growth and profitability erosion is the central financial concern. (Sources: Value Research Online, Company Filing)

Four-Test Sustainability Scorecard

Medicamen Biotech significantly underperforms its pharma peers across every metric. Its dividend yield of 0.31% is less than half the sector average of 0.70%. Its ROE of 3.23% is roughly one-fifth of the pharma sector average (~15%), indicating poor capital efficiency. Despite this, the stock trades at a P/E of ~39×, a 15% premium to the sector average, suggesting overvaluation relative to fundamentals. The payout ratio of 14.07% is also below industry norms, meaning even the modest ₹1 dividend could potentially be higher. For dividend-focused investors, established pharma names offering higher yields with stronger cash flows would likely be more suitable. (Sources: MarketsMojo, Simply Wall St, Screener.in)

Indian Dividend Tax Rules (Current)

Dividends in India are taxable in the hands of shareholders at their applicable income tax slab rate (post-April 2020 regime). TDS at 10% is deducted by the company if total dividend to an individual shareholder exceeds ₹5,000 in a financial year. Non-resident shareholders face a higher TDS rate of 20% (subject to DTAA provisions).

Worked Example: Tax Impact on ₹1 Dividend

At the highest tax bracket, an investor holding 1,000 shares receives only ₹688 net from a ₹1,000 gross dividend, reducing the effective yield to a negligible 0.22%. For an investor to trigger TDS, they would need to hold over 5,000 shares (worth ~₹15.95 Lakh at CMP).

Medicamen Biotech Limited's Re. 1 per share final dividend for FY2025-26 represents a mechanical continuation of a six-year flat payout rather than a meaningful shareholder return. At a yield of 0.31% (post-tax: ~0.22%), the dividend income is negligible for retail investors. The company's core challenge is the persistent disconnect between reported profits and cash generation — four consecutive years of negative OCF while paying dividends is a pattern that deserves scrutiny. On the positive side, the low payout ratio (14.07%), minimal debt (D/E: 0.13), healthy current ratio (2.12), and strong EPS coverage (7.22×) mean the dividend itself is not at risk of being cut. Revenue recovery in FY26 (+21.67%) and Q1 FY27 profit improvement (+178% YoY) offer early signs of stabilization. Investors should focus on whether cash flow improvements materialize before attributing value to this dividend.